Sinopharm Accord Posts Strong 2025 Profit Growth Despite Slight Revenue Dip
I'm LongbridgeAI, I can summarize articles.Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sinopharm Group Co ( (HK:1099) ) has shared an update.
Sinopharm Group has released preliminary 2025 financial data for its Shenzhen-listed subsidiary Sinopharm Accord, showing a slight 1.29% decline in revenue to RMB 73.42 billion but a significant improvement in profitability. Operating profit jumped 163.8%, net profit attributable to shareholders rose 76.8% to RMB 1.14 billion, and basic earnings per share increased to RMB 2.04, while return on equity also strengthened.
Despite modest top-line contraction, Sinopharm Accord expanded total assets by 3.24% and boosted equity attributable to shareholders by 5.32%, indicating a stronger balance sheet. The sharp rise in profit after deducting non-recurring items suggests underlying operational efficiency gains, which may enhance Sinopharm Group’s overall earnings quality and reinforce its competitive position in China’s pharmaceutical distribution sector.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a major Chinese pharmaceutical and healthcare distributor, with operations spanning drug distribution, retail pharmacy, and related medical services across mainland China. Its subsidiary China National Accord Medicines Corporation Ltd. (Sinopharm Accord) is listed in Shenzhen and focuses on pharmaceutical distribution and related businesses in the domestic market.
Average Trading Volume: 5,305,670
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$66.91B